Synthesis and crystal structures of three organoplatinum(II) complexes bearing natural aryl-olefin and quinoline derivatives.

Three organoplatinum(II) complexes bearing natural aryl-olefin and quinoline derivatives, namely, [4-meth-oxy-5-(2-meth-oxy-2-oxoeth-oxy)-2-(prop-2-en-1-yl)phen-yl](quinolin-8-olato)platinum(II), [Pt(C13H15O4)(C9H6NO)], (I), [4-meth-oxy-5-(2-oxo-2-propoxyeth-oxy)-2-(prop-2-en-1-yl)phen-yl](quinoline-2-carboxy-l-ato)platinum(II), [Pt(C15H19O4)(C10H6NO2)], (II), and chlorido-[4-meth-oxy-5-(2-oxo-2-propoxyeth-oxy)-2-(prop-2-en-1-yl)phen-yl](quinoline)-plat-inum(II), [Pt(C15H19O4)Cl(C9H7N)], (III), were synthesized and structurally characterized by IR and 1H NMR spectroscopy, and by single-crystal X-ray diffraction. The results showed that the cyclo-platinated aryl-olefin coordinates with PtII via the carbon atom of the phenyl ring and the C=Colefinic group. The deprotonated 8-hy-droxy-quinoline (C9H6NO) and quinoline-2-carb-oxy-lic acid (C10H6NO2) coordinate with the PtII atom via the N and O atoms in complexes (I) and (II) while the quinoline (C9H7N) coordinates via the N atom in (III). Moreover, the coordinating N atom in complexes (I)-(III) is in the cis position compared to the C=Colefinic group. The crystal packing is characterized by C-H⋯π, C-H⋯O [for (II) and (III)], C-H⋯Cl [for (III) and π-π [for (I)] inter-actions.

Synthesis, crystal structure and anti-cancer activity of the complex chlorido-(η2-ethyl-ene)(quinolin-8-olato-κ2N,O)platinum(II) by experimental and theoretical methods.

The complex [Pt(C9H6NO)Cl(C2H4)], (I), was synthesized and structurally characterized by ESI mass spectrometry, IR, NMR spectroscopy, DFT calculations and X-ray diffraction. The results showed that the deprotonated 8-hy-droxy-quinoline (C9H6NO) coordinates with the PtII atom via the N and O atoms while the ethyl-ene coordinates in the η2 manner and in the trans position compared to the coordinating N atom. The crystal packing is characterized by C-H⋯O, C-H⋯π, Cl⋯π and Pt⋯π inter-actions. Complex (I) showed high selective activity against Lu-1 and Hep-G2 cell lines with IC50 values of 0.8 and 0.4 µM, respectively, 54 and 33-fold more active than cisplatin. In particular, complex (I) is about 10 times less toxic to normal cells (HEK-293) than cancer cells Lu-1 and Hep-G2. Furthermore, the reaction of complex (I) with guanine at the N7 position was proposed and investigated using the DFT method. The results indicated that replacement of the ethyl-ene ligand with guanine is thermodynamically more favorable than the Cl ligand and that the reaction occurs via two consecutive steps, namely the replacement of ethyl-ene with H2O and the water with the guanine mol-ecule.

Crystal structures of three platinacyclic complexes bearing isopropyl eugenoxyacetate and pyridine derivatives.

Three new platinum(II) complexes bearing a eugenol and a pyridine derivative, namely (η2-2-allyl-4-meth-oxy-5-{[(propan-2-yl-oxy)carbon-yl]meth-oxy}phenyl-κC 1)chlorido-(pyridine-κN)platinum(II), [Pt(C15H19O4)Cl(C5H5N)], (I), (η2-2-allyl-4-meth-oxy-5-{[(propan-2-yl-oxy)carbon-yl]meth-oxy}phenyl-κC 1)chlorido-(4-methyl-pyridine-κN)platinum(II), [Pt(C15H19O4)Cl(C6H7N)], (II), and (η2-2-allyl-4-meth-oxy-5-{[(propan-2-yl-oxy)carbon-yl]meth-oxy}phenyl-κC 1)chlorido(pyridine-4-carb-oxy-lic acid-κN)platinum(II), [Pt(C15H19O4)Cl(C6H5NO2)], (III), have been synthesized and further characterized by single-crystal X-ray diffraction. The PtII atoms exhibit the usual distorted square-planar coordination and are surrounded by one Cl atom, one N atom, and a C atom and C=C double bond of the eugenol ligand. The donor N atom of the pyridine ligand occupies a cis position with respect to the double bond. Complexes (I) and (II) crystallize isomorphously in space group P and display a similar crystal packing characterized by C-H⋯O hydrogen bonding, C-H⋯π and π-π inter-actions. However, the presence of the additional methyl group in the 4-methyl-pyridine ligand in (II) disturbs the π-π inter-actions. The crystal packing of (III) is characterized by O-H⋯O hydrogen bonding, resulting in the formation of chains of mol-ecules connected in a head-to-tail fashion and running in the [101] direction. The IC50 values for the HepG2 and KB cell lines are 150.9, 122.3 µM for (I) and 138.9, 93.2 µM for (II), respectively.

Mixed natural arylolefin-quinoline platinum(II) complexes: synthesis, structural characterization and in vitro cytotoxicity studies.

Five new platinum(II) complexes bearing a eugenol and a quinoline derivative, namely [η2-4-allyl-2-methoxy-1-(propoxycarbonylmethoxy)benzene]-trans-dichlorido(quinoline-κN)platinum(II), [PtCl2(C15H20O4)(C9H7N)], (2), {η2-4-allyl-2-methoxy-1-[(propan-2-yloxy)carbonylmethoxy]benzene}-trans-dichlorido(quinoline-κN)platinum(II), [PtCl2(C15H19O4)(C9H7N)], (3), [η2-4-allyl-2-methoxy-1-(propoxycarbonylmethoxy)benzene]chlorido(quinolin-8-olato-κ2N,O)platinum(II), [Pt(C9H6NO)Cl(C15H20O4)], (4), {η2-4-allyl-2-methoxy-1-[(propan-2-yloxy)carbonylmethoxy]benzene}chlorido(quinolin-8-olato-κ2N,O)platinum(II), [Pt(C9H6NO)Cl(C15H20O4)], (5), and [η2-4-allyl-2-methoxy-1-(propoxycarbonylmethoxy)benzene]chlorido(quinolin-2-carboxylato-κ2N,O)platinum(II), [Pt(C10H6NO2)Cl(C15H20O4)], (6), have been synthesized and fully characterized spectroscopically. A single-crystal X-ray diffraction study was carried out for complexes (2) and (4)-(6). PrEug [or 4-allyl-2-methoxy-1-(propoxycarbonylmethoxy)benzene] in (2), (4) and (6), and iPrEug (the propan-2-yloxy analogue of PrEug) in (3) and (5) coordinate with PtII at the ethylenic double bond of the allyl group. In (2)-(6), the donor N atom of the amine group occupies a trans position with respect to the double bond. A comparison of the IC50 values of 0.38-29.23 µM for (2)-(6) with cisplatin, as well as other platinum(II) complexes, indicates an excellent in vitro cytotoxicity against the KB, LU, Hep-G2 and MCF-7 cancer cell lines, with the highest cytotoxic effect (IC50 = 0.38-1.99 µM) being for complexes (4) and (5) bearing a quinolin-8-olate ligand.

Congenital absence of the inferior rectus muscle--diagnosis and management.

BACKGROUND: Congenital absence of the inferior rectus muscle is a rare cause of apparent inferior rectus palsy especially in the absence of associated cranial facial anomalies. METHODS: We report three cases of isolated congenital absence of the inferior rectus muscle and its successful surgical management. RESULTS: Failure of the normal embryologic development of the mesodermal complex around the eye can lead to agenesis of the extraocular muscles. In apparent palsies of the inferior rectus muscle and no definite cause, a high index of suspicion and orbital imaging can confirm the diagnosis of congenitally absent inferior rectus preoperatively. Surgical correction may involve inferior transposition of the horizontal rectus muscles. CONCLUSIONS: Although rare, congenital absence of the inferior rectus muscle is a possible cause of apparent inferior rectus muscle palsy particularly in the absence of another identifiable cause. Strabismus surgery in conjunction with intramuscular botulinum toxin injection can offer significant improvement in function and cosmesis of these patients.